.Pharmacolibrary.Drugs.N_NervousSystem.N03A_Antiepileptics.N03AX21_Retigabine.Retigabine .Pharmacolibrary.Drugs.N_NervousSystem.N03A_Antiepileptics.N03AX21_Retigabine.Retigabine| name: | Retigabine |
| ATC code: | N03AX21 | route: | oral |
| n-compartments | 1 |
Retigabine (also known as ezogabine) is an anticonvulsant medication used as adjunctive therapy in the treatment of partial-onset seizures in epilepsy. It acts primarily as a potassium channel opener (KCNQ potassium channel agonist). Retigabine was approved in the EU and US but has been discontinued due to safety concerns including retinal abnormalities and skin discoloration.
Pharmacokinetics reported for healthy adult volunteers after single oral dose.
Jacob, S, & Nair, AB (2016). An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs. Drugs in R&D 16(4) 303–316. DOI:10.1007/s40268-016-0148-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27766590
Ferron, GM, et al., & Troy, S (2002). Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. Journal of clinical pharmacology 42(2) 175–182. DOI:10.1177/00912700222011210 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11831540